Compare FedEx Corporation (FDX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs GeneDx Holdings Corp — how do they compare? FedEx Corporation trades at $291.71 (market cap $69.04B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: FedEx Corporation is far larger — about 34.2× GeneDx Holdings Corp's market cap, and FedEx Corporation pays a 1.67% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and GeneDx Holdings Corp for 19 Days on average.
| FDX | WGS | |
|---|---|---|
Market Cap | $69.04B | $2.02B |
Volume | 1,287,367 | 734,640 |
Sector | Industrials | Health |
52-Week High | $339.35 | $167.51 |
52-Week Low | $180.87 | $34.51 |
Typical Hold Time | 87 Days | 19 Days |
Enterprise Value | $98.68B | $2.05B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.73, up 0.93% today, with a bearish technical signal but strong fundamentals including a P/E of 15.73 and net income margin of 4.68%. Recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength, while news includes a $300 million electric truck order and shareholder approval of executive pay. Cash flow trends show a projected rebound in 2026 to $7.8 billion net.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and net cash outflows pose risks. Investment appeal lies in valuation discounts and dividend yield, though bearish technicals and economic sensitivity warrant caution for near-term volatility.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
